These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 2128514

  • 1. In vivo studies on the effect of monoamine oxidase inhibitors on dopamine and serotonin metabolism in rat brain areas.
    Clement HW, Grote C, Wesemann W.
    J Neural Transm Suppl; 1990; 32():85-8. PubMed ID: 2128514
    [No Abstract] [Full Text] [Related]

  • 2. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
    Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW.
    J Neurochem; 1990 Sep; 55(3):981-8. PubMed ID: 2117053
    [Abstract] [Full Text] [Related]

  • 3. 1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol depletes catecholamines in rat brain.
    Liptrot J, Holdup D, Phillipson O.
    J Neurochem; 1993 Dec; 61(6):2199-206. PubMed ID: 7504086
    [Abstract] [Full Text] [Related]

  • 4. Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.
    Nguyen TB, Angers M.
    Biochem Pharmacol; 1987 May 15; 36(10):1731-5. PubMed ID: 3109430
    [Abstract] [Full Text] [Related]

  • 5. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J, Miklya I.
    Arch Int Pharmacodyn Ther; 1994 May 15; 328(1):1-15. PubMed ID: 7893186
    [Abstract] [Full Text] [Related]

  • 6. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors.
    Blier P, de Montigny C.
    Neuroscience; 1985 Dec 15; 16(4):949-55. PubMed ID: 3005914
    [Abstract] [Full Text] [Related]

  • 7. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.
    Kato T, Dong B, Ishii K, Kinemuchi H.
    J Neurochem; 1986 Apr 15; 46(4):1277-82. PubMed ID: 2419508
    [Abstract] [Full Text] [Related]

  • 8. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat.
    Garrett MC, Soares-da-Silva P.
    Neuropharmacology; 1990 Oct 15; 29(10):875-9. PubMed ID: 2123970
    [Abstract] [Full Text] [Related]

  • 9. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y, Matsui Y, Iwata N.
    Jpn J Pharmacol; 1991 Jan 15; 55(1):121-8. PubMed ID: 1904113
    [Abstract] [Full Text] [Related]

  • 10. The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.
    Philips SR, Boulton AA.
    J Neurochem; 1979 Jul 15; 33(1):159-67. PubMed ID: 572413
    [No Abstract] [Full Text] [Related]

  • 11. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.
    Celada P, Artigas F.
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Jun 15; 347(6):583-90. PubMed ID: 7689703
    [Abstract] [Full Text] [Related]

  • 12. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.
    Garrick NA, Murphy DL.
    Psychopharmacology (Berl); 1980 Jun 15; 72(1):27-33. PubMed ID: 6781004
    [No Abstract] [Full Text] [Related]

  • 13. Reciprocal changes in striatal dopamine and beta-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors.
    Juorio AV, Greenshaw AJ, Wishart TB.
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Dec 15; 338(6):644-8. PubMed ID: 3149722
    [Abstract] [Full Text] [Related]

  • 14. Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release.
    Halladay AK, Kirschner E, Hesse K, Fisher H, Wagner GC.
    Pharmacol Toxicol; 2001 Nov 15; 89(5):237-48. PubMed ID: 11881977
    [Abstract] [Full Text] [Related]

  • 15. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct 15; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 16. Cumulative effects of irreversible MAO inhibitors in vivo.
    Felner AE, Waldmeier PC.
    Biochem Pharmacol; 1979 Apr 01; 28(7):995-1002. PubMed ID: 444293
    [No Abstract] [Full Text] [Related]

  • 17. Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.
    Sivam SP.
    Neuropeptides; 1993 Jul 01; 25(1):35-45. PubMed ID: 7692341
    [Abstract] [Full Text] [Related]

  • 18. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Wachtel SR, Abercrombie ED.
    J Neurochem; 1994 Jul 01; 63(1):108-17. PubMed ID: 8207420
    [Abstract] [Full Text] [Related]

  • 19. Oxygen inhalation enhances striatal dopamine metabolism and monoamineoxidase enzyme inhibition prevents it: a microdialysis study.
    Adachi YU, Watanabe K, Higuchi H, Satoh T, Vizi ES.
    Eur J Pharmacol; 2001 Jun 22; 422(1-3):61-8. PubMed ID: 11430914
    [Abstract] [Full Text] [Related]

  • 20. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
    Fowler CJ, Mantle TJ, Tipton KF.
    Biochem Pharmacol; 1982 Nov 15; 31(22):3555-61. PubMed ID: 6817759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.